Tesamorelin therapy reduces visceral adipose tissue in HIV lipodystrophy
study003
10.1056/NEJMoa0911289
New England Journal of Medicine
randomized clinical trial
Tesamorelin was studied in patients with HIV-associated lipodystrophy.
Significant reduction in visceral adipose tissue and increase in IGF-1 levels observed.
tesamorelin
fat-loss|hormone-optimization
gh-optimization-stack
tesamorelin-vs-sermorelin
published